摘要
目的探讨重组人脑利钠肽对改善心肌梗死后心力衰竭患者射血分数及脑钠肽的影响。方法方便收集2016年8月—2017年10月该院收治的100例心肌梗死后心力衰竭患者,分为:研究组和对照组。两组基础治疗为利尿剂、洋地黄类药物、β受体阻滞剂、血管紧张素转换酶抑制剂。研究组加用重组人脑利钠肽治疗。对比两组患者治疗前、治疗48 h、治疗72 h射血分数及脑钠肽水平;两组治疗前、治疗48 h、治疗72 h心率及平均动脉压。结果两组患者治疗前射血分数及脑钠肽水平差异无统计学意义(P>0.05);研究组患者治疗48 h、治疗72 h射血分数及脑钠肽水平高于对照组,两组分别为(44.34±4.28)%、(51.65±4.53)%、(356.82±43.05)pg/mL、(415.28±46.82)pg/mL、(41.33±5.11)%、(43.52±6.72)%、(246.82±34.27)pg/mL、(347.82±37.42)pg/mL,差异有统计学意义(t=6.854、5.221、5.854、6.417,P<0.05);两组患者治疗前心率及平均动脉压差异无统计学意义(P>0.05);研究组患者治疗48 h、治疗72 h射心率及平均动脉压低于对照组,两组分别为(94.25±9.34)次/min、(82.34±6.42)次/min、(76.65±6.87)mmHg、(82.56±7.01)mmHg、(105.24±11.75)次/min、(94.25±10.34)次/min、(72.25±4.85)mmHg、(76.35±5.05)mmHg,差异有统计学意义(t=5.205、4.147、4.002、5.471,P<0.05)。结论该文认为重组人脑利钠肽可以提高心肌梗死后心力衰竭患者射血分数及脑钠肽水平,改善心功能。
Objective To investigate the effects of recombinant human brain natriuretic peptide on ejection fraction and brain natriuretic peptide in patients with heart failure after myocardial infarction. Methods A total of 100 patients with heart failure after myocardial infarction from August 2016 to October 2017 were convenient enrolled in the study group and the control group. The basic treatments in the two groups were diuretics, digitalis drugs, beta blockers, and angiotensin converting enzyme inhibitors. The study group was treated with recombinant human brain natriuretic peptide. The two groups were compared before treatment, 48 hours of treatment, 72 hours of ejection fraction and brain natriuretic peptide level;two groups before treatment, 48 hours of treatment, 72 hours of heart rate and mean arterial pressure. Results There was no significant difference in the ejection fraction and brain natriuretic peptide between the two groups(P>0.05). The study group received 48 hours of treatment, 72 hours of ejection fraction and brain natriuretic peptide level were higher than the control group. They were(44.34±4.28)%,(51.65±4.53)%,(356.82±43.05)pg/mL,(415.28±46.82)pg/mL,(41.33±5.11)%,(43.52±6.72)%,(246.82 ±34.27)pg/mL, 347.82 ±37.42)pg/mL, the difference was statistically significant(t =6.854, 5.221, 5.854, 6.417, P <0.05);there was no significant difference in pre-treatment heart rate and mean arterial pressure between the two groups(P>0.05);the heart rate and mean arterial pressure were lower than the control group at 48 hours, 72 hours of treatment, and the two groups were(94.25±9.34)times/min,(82.34±6.42)times/min,(76.65±6.87)mmHg,(82.56±7.01)mmHg,(105.24±11.75)times/min,(94.25 ±10.34)times/min,(72.25 ±4.85)mmHg,(76.35 ±5.05)mmHg, the difference was statistically significant(t =5.205, 4.147, 4.002, 5.471, P<0.05). Conclusion This study suggests that recombinant human brain natriuretic peptide can improve ejection fraction and brain natriuretic peptide levels in patients with heart failure after myocardial infarction and improve cardiac function.
作者
周锐
ZHOU Rui(Department of Cardiology, Shihezi People's Hospital, Shihezi, Xinjiang, 832000 China)
出处
《中外医疗》
2019年第7期124-126,共3页
China & Foreign Medical Treatment
关键词
重组人脑利钠肽
心肌梗死
心力衰竭
Recombinant human brain natriuretic peptide
Myocardial infarction
Heart failure
